These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20970976)

  • 1. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease.
    Bernstein JA; Liu N; Knorr BA; Smugar SS; Hanley WD; Reiss TF; Greenberg S
    Respir Med; 2011 Mar; 105(3):392-401. PubMed ID: 20970976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma.
    Wasfi YS; Villarán C; de Tilleghem Cle B; Smugar SS; Hanley WD; Reiss TF; Knorr BA
    Respir Med; 2012 Jan; 106(1):34-46. PubMed ID: 21945511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
    Fogarty C; Hattersley H; Di Scala L; Drollmann A
    Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
    Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
    N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
    Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
    Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities].
    Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N;
    Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a randomized, double-blind, double-dummy, efficacy and safety study in patients with chronic obstructive pulmonary disease].
    Zheng JP; Kang J; Cai BQ; Zhou X; Cao ZL; Bai CX; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jun; 29(6):363-7. PubMed ID: 17045014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
    Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
    Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled sodium pyruvate improved FEV1 and decreased expired breath levels of nitric oxide in patients with chronic obstructive pulmonary disease.
    Votto JJ; Bowen JB; Barton RW; Thrall RS
    J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):329-34. PubMed ID: 18800883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD.
    Kobayashi S; Suzuki S; Niikawa H; Sugawara T; Yanai M
    Respirology; 2009 Jul; 14(5):675-9. PubMed ID: 19476597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
    Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
    Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.
    Kerstjens HA; Bjermer L; Eriksson L; Dahlström K; Vestbo J
    Respir Med; 2010 Sep; 104(9):1297-303. PubMed ID: 20466530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
    Bateman E; Feldman G; Kilbride S; Brooks J; Mehta R; Harris S; Maden C; Crater G
    Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
    Hordvik NL; Sammut PH; Judy CG; Colombo JL
    Pediatr Pulmonol; 2002 Oct; 34(4):287-96. PubMed ID: 12205570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease.
    Ryan S; Doherty LS; Rock C; Nolan GM; McNicholas WT
    Respiration; 2010; 79(6):475-81. PubMed ID: 19684384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.